GeneDx (US:WGS) ZACKS·2025-04-30 12:46Company Performance - GeneDx Holdings Corp. reported quarterly earnings of $0.28 per share, exceeding the Zacks Consensus Estimate of $0.11 per share, and a significant improvement from a loss of $0.33 per share a year ago, representing an earnings surprise of 154.55% [1] - The company achieved revenues of $87.12 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 9.03%, and showing an increase from $62.42 million in the same quarter last year [2] - Over the last four quarters, GeneDx Holdings has consistently surpassed consensus EPS estimates and revenue estimates [2] Stock Performance - GeneDx Holdings shares have increased approximately 52.2% since the beginning of the year, contrasting with a decline of -5.5% in the S&P 500 [3] - The current consensus EPS estimate for the upcoming quarter is $0.23 on revenues of $86.8 million, and for the current fiscal year, it is $0.97 on revenues of $359.7 million [7] Industry Outlook - The Medical Services industry, to which GeneDx Holdings belongs, is currently ranked in the top 29% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5]